Perspective Therapeutics, Inc.

What they do

Since the 2023 merger of Isoray and Viewpoint, Perspective has operated primarily as a research and development company focused on a four-program 212Pb pipeline: VMT-alpha-NET, VMT01, PSV359 and PSV594. It has not received regulatory approval to market any current product candidate and has generated no product-sales revenue other than from its discontinued brachytherapy business. The company is also building out a regional manufacturing network to supply its own clinical trials and, if approved, commercial demand.

Revenue drivers

• Product sales — No revenue from current product candidates; the 10-K states the company has not generated any revenue from product sales other than its discontinued brachytherapy business, and annual revenue fell to $1.4M in 2023 from $10.1M in 2021.
• Bamzireotide navoxetan (VMT-alpha-NET) — Lead pipeline asset for SSTR2-positive neuroendocrine tumors and meningioma; 76 NET patients across four cohorts and one meningioma patient treated as of July 31, 2026, with a Phase 3 study being prepared. Pre-revenue.
• Lapemelanotide zapixetar (VMT01) — MC1R-positive melanoma program, dosed as monotherapy or with nivolumab; 27 patients enrolled as of July 31, 2026, with a cumulative 9 mCi dose in up to three treatments every eight weeks as the focus. Pre-revenue.
• PSV359 and PSV594 — PSV359 targets FAP-alpha-positive solid tumors (17 patients treated across three cohorts as of July 31, 2026); PSV594 in CCK2R-positive solid tumors remains pre-IND. Both are pre-revenue.

Recent performance

For the three months ended June 30, 2026, research and development expenses were $21.5 million, compared with $16.6 million in the prior-year period. Cash, cash equivalents and short-term investments were approximately $237 million at June 30, 2026, up from approximately $145 million at December 31, 2025; the balance sheet shows total assets of $392.0 million, total liabilities of $68.2 million and shareholder equity of $323.9 million at that date, with cash and equivalents of $48.5 million and long-term debt of $1.6 million. The company reported annual net losses of $46.5 million in 2023, $79.3 million in 2024 and $103.1 million in 2025, with operating cash use of $82.5 million in 2025. No dividends were paid in 2024 or 2025.

Strategy

Management is preparing VMT-alpha-NET for a Phase 3 study evaluating a proposed cumulative 20 mCi (740 MBq) dose given in up to four treatments every eight weeks, with clinical site activation targeted around year-end 2026 subject to regulatory feedback. It is also expanding manufacturing: construction of the Chicago metro site is expected to complete in early 2027, followed by the Los Angeles metro site in the second half of 2027, bringing the network to four regional sites by the end of 2027. The company states it has sufficient isotope access and manufacturing capacity to support ongoing studies and the planned Phase 3. In July 2026, Paul Lyne, Ph.D. was appointed Chief Science Officer.

Risks

• No approved products or product revenue — The company has not received regulatory approval to market any current product candidate and has generated no product-sales revenue other than from its discontinued brachytherapy business.
• Significant and growing net losses — Net losses widened from $46.5 million in 2023 to $79.3 million in 2024 and $103.1 million in 2025, and expenses are expected to continue increasing with development and manufacturing investment.
• Dependence on regulatory and trial timing — The planned VMT-alpha-NET Phase 3 study and site activation around year-end 2026 are subject to regulatory feedback and protocol finalization, and the 10-K notes risks including FDA disruptions from lapses in appropriations or decreased funding.
• Preliminary data may not be confirmed — The 10-K states that unconfirmed responses reported in preliminary or interim clinical data may not ultimately result in confirmed responses after follow-up evaluations.

Outlook

Management states that cash, cash equivalents and short-term investments of approximately $237 million as of June 30, 2026 are sufficient to fund current planned clinical milestones and operational investments into late 2027. Phase 3 site activation for VMT-alpha-NET is targeted around year-end 2026, subject to regulatory feedback, with updated NET data expected at ESMO on October 23, 2026. The next clinical update for PSV359 is planned in 2027, and the manufacturing network is expected to reach four regional sites by the end of 2027.